Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $37
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $36 to $37.
Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $36 to $37.